# Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK

> **NCT04532645** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 342 (actual)

## Conditions studied

- Ovary Cancer

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT04532645
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-07
- **Primary completion:** 2024-09-27
- **Final completion:** 2024-09-27
- **Target enrollment:** 342 (ACTUAL)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04532645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04532645, "Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04532645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*